Table 1.
The expression of DLL3 in SCLC.
| Country | Sample size | DLL3 positive rate | Survival | Reference |
|---|---|---|---|---|
| China | 335 | DLL3-low(38%) DLL3-high(62%) |
DLL3-high (OS) < DLL3-low (OS) |
(44) |
| China | 38 | 100% | DLL3-high(MST:12months) DLL3-low (MST:23months) |
(45) |
| China | 247 | DLL3-low(24%) DLL3-high(76%) |
NS | (39) |
| Japan | 63 | 83% | DLL3-high(OS:12.5months) DLL3-low(OS:15.7months) |
(41) |
| Japan | 95 | 83% | DLL3-high(OS:24.4months) DLL3-low (OS:33.3months) |
(40) |
| America | 44 | 79.5% | NS | (47) |
| Sweden | 46 | 83% | NE | (48) |
| Germany | 42 | chemonaive 86.6% chemorelapsed 80% |
NS | (49) |
OS, overall survival; MST, median survival time; NE, Not evaluated; NS, No differences.